APE1/Ref-1 Role in Redox Signaling: Translational Applications of Targeting the Redox Function of the DNA Repair/Redox Protein APE1/Ref-1

The heterogeneity of most cancers diminishes the treatment effectiveness of many cancer-killing regimens. Thus, treatments that hold the most promise are ones that block multiple signaling pathways essential to cancer survival. One of the most promising proteins in that regard is APE1, whose reduction-oxidation activity influences multiple cancer survival mechanisms, including growth, proliferation, metastasis, angiogenesis, and stress responses. With the continued research using APE1 redox specific inhibitors alone or coupled with developing APE1 DNA repair inhibitors it will now be possible to further delineate the role of APE1 redox, repair and protein-protein interactions. Previously, use of siRNA or over expression approaches, while valuable, do not give a clear picture of the two major functions of APE1 since both techniques severely alter the cellular milieu. Additionally, use of the redox-specific APE1 inhibitor, APX3330, now makes it possible to study how inhibition of APE1’s redox signaling can affect multiple tumor pathways and can potentiate the effectiveness of existing cancer regimens. Because APE1 is an upstream effector of VEGF, as well as other molecules that relate to angiogenesis and the tumor microenvironment, it is also being studied as a possible treatment for age-related macular degeneration and diabetic retinopathy. This paper reviews all of APE1’s functions, while heavily focusing on its redox activities. It also discusses APE1’s altered expression in many cancers and the therapeutic potential of selective inhibition of redox regulation, which is the subject of intense preclinical studies

DeWitt Wallace Library Annual Report 2013-2014

Summary of library and media services activities for 2013-201

DeWitt Wallace Library Biennial Report 2011-2013

Summary of library activities for 2011-201

Integrin beta 1 coordinates survival and morphogenesis of the embryonic lineage upon implantation and pluripotency transition

At implantation, the embryo establishes contacts with the maternal endometrium. This stage is associated with a high incidence of preclinical pregnancy losses. While the maternal factors underlying uterine receptivity have been investigated, the signals required by the embryo for successful peri-implantation development remain elusive. To explore these, we studied integrin beta 1 signaling, as embryos deficient for this receptor degenerate at implantation. We demonstrate that the coordinated action of pro-survival signals and localized actomyosin suppression via integrin beta 1 permits the development of the embryo beyond implantation. Failure of either process leads to developmental arrest and apoptosis. Pharmacological stimulation through fibroblast growth factor 2 (FGF2) and insulin-like growth factor 1 (IGF1), coupled with ROCK-mediated actomyosin inhibition, rescues the deficiency of integrin beta 1, promoting progression to post-implantation stages. Mutual exclusion between integrin beta 1 and actomyosin seems to be conserved in the human embryo, suggesting the possibility that these mechanisms could also underlie the transition of the human epiblast from pre- to post-implantation

Transcript of Video File: Panel 4 - Severe or Pervasive: Towards Empowering Workers

This is a video transcript of a panel session in the Enhancing Anti-Discrimination Laws in Education and Employment symposium

Mass spectrometric gas composition measurements associated with jet interaction tests in a high-enthalpy wind tunnel

Knowledge of test gas composition is important in wind-tunnel experiments measuring aerothermodynamic interactions. This paper describes measurements made by sampling the top of the test section during runs of the Langley 7-Inch High-Temperature Tunnel. The tests were conducted to determine the mixing of gas injected from a flat-plate model into a combustion-heated hypervelocity test stream and to monitor the CO2 produced in the combustion. The Mass Spectrometric (MS) measurements yield the mole fraction of N2 or He and CO2 reaching the sample inlets. The data obtained for several tunnel run conditions are related to the pressures measured in the tunnel test section and at the MS ionizer inlet. The apparent distributions of injected gas species and tunnel gas (CO2) are discussed relative to the sampling techniques. The measurements provided significant real-time data for the distribution of injected gases in the test section. The jet N2 diffused readily from the test stream, but the jet He was mostly entrained. The amounts of CO2 and Ar diffusing upward in the test section for several run conditions indicated the variability of the combustion-gas test-stream composition

Machine translation for subtitling: a large-scale evaluation

This article describes a large-scale evaluation of the use of Statistical Machine Translation for professional subtitling. The work was carried out within the FP7 EU-funded project SUMAT and involved two rounds of evaluation: a quality evaluation and a measure of productivity gain/loss. We present the SMT systems built for the project and the corpora they were trained on, which combine professionally created and crowd-sourced data. Evaluation goals, methodology and results are presented for the eleven translation pairs that were evaluated by professional subtitlers. Overall, a majority of the machine translated subtitles received good quality ratings. The results were also positive in terms of productivity, with a global gain approaching 40%. We also evaluated the impact of applying quality estimation and filtering of poor MT output, which resulted in higher productivity gains for filtered files as opposed to fully machine-translated files. Finally, we present and discuss feedback from the subtitlers who participated in the evaluation, a key aspect for any eventual adoption of machine translation technology in professional subtitlin

APE1/Ref-1 knockdown in pancreatic ductal adenocarcinoma – characterizing gene expression changes and identifying novel pathways using single-cell RNA sequencing

Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1 or APE1) is a multifunctional protein that regulates numerous transcription factors associated with cancer-related pathways. Because APE1 is essential for cell viability, generation of APE1-knockout cell lines and determining a comprehensive list of genes regulated by APE1 has not been possible. To circumvent this challenge, we utilized single-cell RNA sequencing to identify differentially expressed genes (DEGs) in relation to APE1 protein levels within the cell. Using a straightforward yet novel statistical design, we identified 2837 genes whose expression is significantly changed following APE1 knockdown. Using this gene expression profile, we identified multiple new pathways not previously linked to APE1, including the EIF2 signaling and mechanistic target of Rapamycin pathways and a number of mitochondrial-related pathways. We demonstrate that APE1 has an effect on modifying gene expression up to a threshold of APE1 expression, demonstrating that it is not necessary to completely knockout APE1 in cells to accurately study APE1 function. We validated the findings using a selection of the DEGs along with siRNA knockdown and qRT-PCR. Testing additional patient-derived pancreatic cancer cells reveals particular genes (ITGA1, TNFAIP2, COMMD7, RAB3D) that respond to APE1 knockdown similarly across all the cell lines. Furthermore, we verified that the redox function of APE1 was responsible for driving gene expression of mitochondrial genes such as PRDX5 and genes that are important for proliferation such as SIPA1 and RAB3D by treating with APE1 redox-specific inhibitor, APX3330. Our study identifies several novel genes and pathways affected by APE1, as well as tumor subtype specificity. These findings will allow for hypothesis-driven approaches to generate combination therapies using, for example, APE1 inhibitor APX3330 with other approved FDA drugs in an innovative manner for pancreatic and other cancer treatments